|AI Robots Name||P/L||Entry Price, $||Profit, $/%|
|AI Robots Name||P/L||Entry Price, $||Profit, $/%|
The Aroon Indicator for ABIO entered a downward trend on February 23, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 239 similar instances where the Aroon Indicator formed such a pattern. In 206 of the 239 cases the stock moved lower. This puts the odds of a downward move at 86%.
The Momentum Indicator moved below the 0 level on March 13, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ABIO as a result. In of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABIO turned negative on March 20, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for ABIO moved below the 200-day moving average on March 03, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for ABIO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABIO advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.702) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.071).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ABIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of genetic therapies for heart failure and cardiovascular diseases
A.I.dvisor indicates that over the last year, ABIO has been loosely correlated with OCGN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ABIO jumps, then OCGN could also see price increases.
|OCGN - ABIO|
|MDGL - ABIO|
|AVRO - ABIO|
|FATE - ABIO|
|HRTX - ABIO|